The 2026 update of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) Breast Panel recommendations covers the use of treatment-relevant biomarkers in both early and advanced breast cancer, providing updated guidance for clinical practice.
The panel issued updated consensus recommendations on biomarker testing and clinical application across breast cancer subtypes (early and advanced stages); specific numerical outcomes are not reported as this is a guideline/consensus document.
As a consensus-based guideline update, recommendations reflect expert opinion and may not fully account for all emerging biomarker data published close to the 2026 update date; applicability may vary by healthcare system and biomarker assay availability.
Clinicians managing early or advanced breast cancer should consult the 2026 AGO update to align biomarker testing practices—such as hormone receptor, HER2, and emerging markers—with the latest evidence-based recommendations. These guidelines can directly inform treatment sequencing and eligibility for targeted therapies.
Explore related topics
